Current evaluation and management of excessive daytime sleepiness

Canadian Journal of Neurological Sciences

Volumn 37, Issue 2, 2010, Pages 167-176

  Boulos, M I ^a   Murray, B J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; ARMODAFINIL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE; LITHIUM CARBONATE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT; OPIATE; OXYBATE SODIUM; PEMOLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

BEHAVIOR THERAPY; BRAIN DAMAGE; CATAPLEXY; CIRCADIAN RHYTHM SLEEP DISORDER; CLINICAL EVALUATION; CLINICAL TRIAL; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; EPILEPSY; EPWORTH SLEEPINESS SCALE; HUMAN; HYPERSOMNIA; LIVER FAILURE; MENTAL DISEASE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MYOTONIC DYSTROPHY; NARCOLEPSY; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; PARKINSON DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; QUALITY OF LIFE; RATING SCALE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP APNEA SYNDROME; SLEEP DEPRIVATION; SLEEP DISORDER; SOMNOLENCE; STROKE; WAKEFULNESS;

EID: 76649139790     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100009896     Document Type: Review

References (105)

1. American Academy of Sleep Medicine. The international classification of sleep disorders: diagnostic and coding manual. 2nd ed.Westchester, Ill.: American Academy of Sleep Medicine; 2005.
2. Young TB. Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence. J Clin Psychiatry. 2004;65 Suppl 16:12-16
3. Gibson ES, Powles AC, Thabane L, O'Brien S, Molnar DS, Trajanovic N, et al. "Sleepiness" is serious in adolescence: two surveys of 3235 Canadian students. BMC Public Health. 2006;6:116.
4. Masa JF, Rubio M, Findley LJ. Habitually sleepy drivers have a high frequency of automobile crashes associated with respiratory disorders during sleep. Am J Respir Crit Care Med. 2000 Oct; 162(4 Pt 1):1407-1412
5. Howard ME, Desai AV, Grunstein RR, Hukins C, Armstrong JG, Joffe D, et al. Sleepiness, sleep-disordered breathing, and accident risk factors in commercial vehicle drivers. Am J Respir Crit Care Med. 2004 Nov 1;170(9):1014-1021
6. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep. 1994 Feb;17(1):84-93.
7. Webb WB. The cost of sleep-related accidents: a reanalysis. Sleep. 1995 May;18(4):276-280
8. Lyznicki JM, Doege TC, Davis RM, Williams MA. Sleepiness, driving, and motor vehicle crashes. Council on ScientificAffairs, American Medical Association. JAMA. 1998 Jun 17;279(23): 1908-1913
9. George CF. Sleep apnea, alertness, and motor vehicle crashes. Am J Respir Crit Care Med. 2007 Nov 15;176(10):954-956
10. Philip P, Vervialle F, Le Breton P, Taillard J, Horne JA. Fatigue, alcohol, and serious road crashes in France: factorial study of national data. BMJ. 2001 Apr 7;322(7290):829-830
11. Connor J, Norton R,Ameratunga S, Robinson E, Civil I, Dunn R, et al. Driver sleepiness and risk of serious injury to car occupants: population based case control study. BMJ. 2002 May 11;324 (7346):1125.
12. Young T, Blustein J, Finn L, Palta M. Sleep-disordered breathing and motor vehicle accidents in a population-based sample of employed adults. Sleep. 1997 Aug;20(8):608-613
13. Krieger J, Meslier N, Lebrun T, Levy P, Phillip-Joet F, Sailly JC, et al. Accidents in obstructive sleep apnea patients treated with nasal continuous positive airway pressure: a prospective study. The Working Group ANTADIR, Paris and CRESGE, Lille, France. Association Nationale de Traitement a Domicile des Insuffisants Respiratoires. Chest. 1997 Dec;112(6):1561-1566
14. Dawson D, Reid K. Fatigue, alcohol and performance impairment. Nature. 1997 Jul 17;388(6639):235.
15. Arnedt JT, Owens J, Crouch M, Stahl J, Carskadon MA. Neurobehavioral performance of residents after heavy night call vs after alcohol ingestion. JAMA. 2005 Sep 7;294(9):1025-1033
16. Suzuki K, Ohida T, Kaneita Y, Yokoyama E, Uchiyama M. Daytime sleepiness, sleep habits and occupational accidents among hospital nurses. J Adv Nurs. 2005 Nov;52(4):445-453
17. Landrigan CP, Rothschild JM, Cronin JW, Kaushal R, Burdick E, Katz JT, et al. Effect of reducing interns' work hours on serious medical errors in intensive care units. N Engl J Med. 2004 Oct 28;351(18):1838-1848
18. Mulgrew AT, Ryan CF, Fleetham JA, Cheema R, Fox N, Koehoorn M, et al. The impact of obstructive sleep apnea and daytime sleepiness on work limitation. Sleep Med. 2007 Dec;9(1):42-53.
19. Reilly JJ, Armstrong J, Dorosty AR, Emmett PM, Ness A, Rogers I, et al. Early life risk factors for obesity in childhood: cohort study. BMJ. 2005 Jun 11;330(7504):1357.
20. Morgenthaler TI, Kapur VK, Brown T, Swick TJ, Alessi C, Aurora RN, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Dec 1;30 (12):1705-1711
21. Wise MS, Arand DL, Auger RR, Brooks SN,Watson NF. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Dec 1;30(12):1712-1727
22. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000 May 11;342(19):1378-1384
23. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005 Nov 10;353(19):2034-2041
24. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoeahypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005 Mar 19- 25;365(9464):1046-1053
25. Scammell TE. The neurobiology, diagnosis, and treatment of narcolepsy. Ann Neurol. 2003 Feb;53(2):154-166
26. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep. 1994 Dec;17 Suppl 8:S60-7.
27. Chemelli RM,Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999 Aug 20;98(4):437-451
28. Lin L, Faraco J, Li R, Kadotani H, RogersW, Lin X, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell. 1999 Aug 6;98(3): 365-376
29. Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007 Jun;8(4):373-399
30. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron. 2000 Sep;27(3):469-474
31. Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM. Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007 Oct 1; 30(10):1274-1281
32. Arnulf I, Lin L, Gadoth N, File J, Lecendreux M, Franco P, et al. Kleine-Levin syndrome: a systematic study of 108 patients. Ann Neurol. 2008 Apr;63(4):482-493
33. Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, et al. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders.An American Academy of Sleep Medicine report. Sleep. 2007 Nov 1;30(11):1445-1459
34. Sack RL, Brandes RW, Kendall AR, Lewy AJ. Entrainment of freerunning circadian rhythms by melatonin in blind people. N Engl J Med. 2000 Oct 12;343(15):1070-1077
35. Winkelman JW, Sethi KD, Kushida CA, Becker PM, Koester J, Cappola JJ, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology. 2006 Sep 26;67(6):1034-1039
36. Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med. 2008 Oct;9(7):715-726
37. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord. 2008 Dec 15;23(16):2267-2302
38. Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord. 2003 Jun;18(6):659-667
39. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep. 2002 Mar 15;25 (2):120-138
40. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain. 2007 Jun;130(Pt 6):1586-1595
41. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002 Jan 23-30;287(4):455-463
42. Comella CL. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl. 2006 (70):349-355
43. Bhatt MH, Podder N, Chokroverty S. Sleep and neurodegenerative diseases. Semin Neurol. 2005 Mar;25(1):39-51.
44. McCurry SM, Ancoli-Israel S. Sleep dysfunction in Alzheimer's disease and other dementias. Curr Treat Options Neurol. 2003 May;5(3):261-272
45. Auger C, Montplaisir J, Duquette P. Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology. 2005 Nov 22;65(10):1652-1653
46. Bassetti CL. Sleep and stroke. Semin Neurol. 2005 Mar;25(1): 19-32.
47. Kaneko Y, Hajek VE, Zivanovic V, Raboud J, Bradley TD. Relationship of sleep apnea to functional capacity and length of hospitalization following stroke. Sleep. 2003 May 1;26(3): 293-297
48. Mendez M, Radtke RA. Interactions between sleep and epilepsy. J Clin Neurophysiol. 2001 Mar;18(2):106-127
49. Malow BA, Levy K, Maturen K, Bowes R. Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology. 2000 Oct 10;55(7):1002-1007
50. Guilleminault C, Shergill RP. Sleep-disordered breathing in neuromuscular disease. Curr Treat Options Neurol. 2002 Mar;4 (2):107-112
51. Laberge L, Begin P, Dauvilliers Y, Beaudry M, Laforte M, Jean S, et al. A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6)642-646
52. Cochen V, Arnulf I, Demeret S, Neulat ML, Gourlet V, Drouot X, et al. Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barre syndrome. Brain. 2005 Nov;128(Pt 11):2535-2545
53. Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T. Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci. 1999 Mar 15;164(1):82-88
54. Saper CB, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001 Dec;24 (12):726-731
55. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, Mignot E, et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology. 2005 Jul 12;65(1):147-149
56. Benz RL, Pressman MR, Hovick ET, Peterson DD. Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis. 2000 Jun;35(6):1052-1060
57. Doghramji K, editor. The sleep-psychiatry interface. Philadelphia: Elsevier; 2006.
58. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IVTR. 4th ed. Washington, DC: American Psychiatric Association; 2000.
59. Rapoport MJ, Lanctot KL, Streiner DL, Bedard M, Vingilis E, Murray B, et al. Benzodiazepine use and driving: a metaanalysis. J Clin Psychiatry. 2009 May;70(5):663-673
60. Roth T, Roehrs TA. Etiologies and sequelae of excessive daytime sleepiness. Clin Ther. 1996 Jul-Aug;18(4):562-76; discussion 1.
61. Vermeeren A. Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs. 2004;18(5):297-328.
62. Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.
63. Douglass AB, Bornstein R, Nino-Murcia G, Keenan S, Miles L, Zarcone VP, Jr., et al. The Sleep Disorders Questionnaire. I: Creation and multivariate structure of SDQ. Sleep. 1994 Mar;17 (2):160-167
64. Weatherwax KJ, Lin X, Marzec ML, Malow BA. Obstructive sleep apnea in epilepsy patients: the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ) is a useful screening instrument for obstructive sleep apnea in a disease-specific population. Sleep Med. 2003 Nov;4(6):517-521
65. Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology. 2009 Mar 17;72(11):955-960
66. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-545
67. Miletin MS, Hanly PJ. Measurement properties of the Epworth sleepiness scale. Sleep Med. 2003 May;4(3):195-199
68. Chervin RD. Epworth sleepiness scale? Sleep Med. 2003 May;4(3): 175-176
69. Chervin RD, Aldrich MS. The Epworth Sleepiness Scale may not reflect objective measures of sleepiness or sleep apnea. Neurology. 1999 Jan 1;52(1):125-131
70. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: a new approach. Psychophysiology. 1973 Jul;10(4):431-436
71. Iber C, American Academy of Sleep Medicine. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. Westchester, IL: American Academy of Sleep Medicine; 2007.
72. Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR, Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 1986 Dec;9(4):519-524
73. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, Lee- Chiong T, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005 Jan 1;28(1):113-121
74. Wise MS. Objective measures of sleepiness and wakefulness: application to the real world? J Clin Neurophysiol. 2006 Feb;23 (1):39-49.
75. Lim J, Dinges DF. Sleep deprivation and vigilant attention. Ann N Y Acad Sci. 2008;1129:305-322
76. Doran SM, Van Dongen HP, Dinges DF. Sustained attention performance during sleep deprivation: evidence of state instability. Arch Ital Biol. 2001 Apr;139(3):253-267
77. Baillargeon L, Landreville P, Verreault R, Beauchemin JP, Gregoire JP, Morin CM. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003 Nov 11;169(10):1015-1020
78. Rogers AE, Aldrich MS, Lin X. A comparison of three different sleep schedules for reducing daytime sleepiness in narcolepsy. Sleep. 2001 Jun 15;24(4):385-391
79. Won CH, Li KK, Guilleminault C. Surgical treatment of obstructive sleep apnea: upper airway and maxillomandibular surgery. Proc Am Thorac Soc. 2008 Feb 15;5(2):193-199
80. USModafinil in NarcolepsyMulticenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 1998 Jan;43(1):88-97.
81. USModafinil in NarcolepsyMulticenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: Neurology. 2000 Mar 14;54(5): 1166-1175
82. Schwartz JR, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003 Sep-Oct;26(5):252-257
83. Schwartz JR, Nelson MT, Schwartz ER, Hughes RJ. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol. 2004 Mar-Apr;27(2):74-79
84. Schwartz JR, Feldman NT, Bogan RK. Dose effects of modafinil in sustaining wakefulness in narcolepsy patients with residual evening sleepiness. J Neuropsychiatry Clin Neurosci. 2005 Summer;17(3):405-412
85. Ivanenko A, Tauman R, Gozal D. Modafinil in the treatment of excessive daytime sleepiness in children. Sleep Med. 2003 Nov; 4(6):579-582
86. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(5):695-700.
87. Hogl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002 Dec;25(8): 905-909
88. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol. 2002 Mar-Apr;25(2):111-114
89. Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636-1639
90. Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord. 2003 Jun;13(5): 357-364
91. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):179-183
92. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an openlabel study. J Neurol. 2002 Aug;249(8):983-987
93. Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med. 2001 Nov 1;164(9):1675-1681
94. Czeisler CA, Walsh JK, Roth T, Hughes RJ, Wright KP, Kingsbury L, et al. Modafinil for excessive sleepiness associated with shiftwork sleep disorder. N Engl J Med. 2005 Aug 4;353(5):476-486
95. Harsh JR, Hayduk R, Rosenberg R, Wesnes KA, Walsh JK, Arora S, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006 Apr;22(4):761-774
96. U.S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002 Feb 1;25(1):42-49
97. U.S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004 Mar;5 (2):119-123
98. Xyrem International Study Group. Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a doubleblind, placebo-controlled study in 228 patients. Sleep Med. 2005 Sep;6(5):415-421
99. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006 Jul 1;29(7): 939-46.
100. Xyrem International Study Group. A double-blind, placebocontrolled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005 Oct 15;1(4): 391-7.
101. Mamelak M, Black J, Montplaisir J, Ristanovic R. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep. 2004 Nov 1;27(7):1327-34.
102. U.S. Xyrem Multicenter Study Group. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003 Feb 1;26(1):31-5.
103. van der Meche FG, Bogaard JM, van der Sluys JC, Schimsheimer RJ, Ververs CC, Busch HF. Daytime sleep in myotonic dystrophy is not caused by sleep apnoea. J Neurol Neurosurg Psychiatry. 1994 May;57(5):626-8.
104. Poppe M, Friebel D, Reuner U, Todt H, Koch R, Heubner G. The Kleine-Levin syndrome - effects of treatment with lithium. Neuropediatrics. 2003 Jun;34(3):113-9.
105. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007 Dec 26;27(52):14239-14247